Black Diamond Therapeutics, Inc. — Director's Dealing 2021

Apr 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-04-12

Reporting Person: Hatzis-Schoch Brent (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-12	Common Stock	M	4078	$3.20	Acquired	12478	Direct
2021-04-12	Common Stock	S	4078	$25.00	Disposed	8400	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-12	Stock Option (Right to Buy)	$3.20	M	179915	Disposed	2029-06-11	Common Stock (4078)	Direct

Footnotes

F1: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F2: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.